Literature DB >> 29049857

Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma.

Arvind C Mohan1, Rajkumar Venkatramani1,2, M Fatih Okcu1,2, Jed G Nuchtern1,2, Sanjeev A Vasudevan1,2, Anita Mahajan3, Nino C Rainusso1,2, Wendy Allen-Rhoades1,2, Murali Chintagumpala1,2, Arnold C Paulino1,2,4.   

Abstract

PURPOSE: To determine the impact of surgery and/or radiation therapy on distant metastatic sites (DMS) in children with stage IV rhabdomyosarcoma (RMS).
METHODS: A retrospective chart review was conducted on all patients with stage IV RMS at Texas Children's Hospital from 1992 to 2012. Data analyzed included age, gender, primary site, histologic subtype, number and sites of metastases, treatment including local therapy to DMS, and Oberlin score.
RESULTS: The 5-year progression-free survival (PFS) and overall survival (OS) rates were 20% and 25%. The 5-year PFS in patients receiving local therapy to all DMS (n = 16) and to less than all DMS (n = 19) was 31.3% versus 0% (P = 0.002), whereas the 5-year OS was 37.3% versus 0% (P < 0.001), respectively. The 5-year PFS in patients with isolated lung metastasis versus other types of metastasis was 29% versus 7% (P = n.s.), whereas the 5-year OS was 43% versus 10% (P = 0.01). The 5-year pulmonary local control was improved by the use of whole lung irradiation (WLI; 56% vs. 10%, P = 0.03).
CONCLUSIONS: Local treatment to all metastatic sites was associated with improved PFS and OS at 5 years. The use of WLI improved pulmonary control in patients with lung metastasis. We recommend an aggressive approach including local therapy to DMS in children with stage IV RMS.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  local control; metastasis; radiotherapy; rhabdomyosarcoma; whole lung irradiation

Mesh:

Year:  2017        PMID: 29049857     DOI: 10.1002/pbc.26859

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging.

Authors:  Monika Scheer; Tobias Dantonello; Peter Brossart; Dagmar Dilloo; Lothar Schweigerer; Simone Feuchtgruber; Monika Sparber-Sauer; Christian Vokuhl; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak; Thekla von Kalle
Journal:  Pediatr Radiol       Date:  2018-01-24

Review 2.  Surgical management and outcomes of intracranial metastatic Wilms' tumor in the pediatric population: a case series.

Authors:  Peter J Madsen; Raphia K Rahman; Yash A Patel; Shih-Shan Lang; Phillip B Storm; Alexander M Tucker
Journal:  Childs Nerv Syst       Date:  2022-04-04       Impact factor: 1.532

3.  Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities.

Authors:  Stanislav Lazarev; Brian H Kushner; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-02       Impact factor: 7.038

4.  Efficacy and tolerability of stereotactic body radiotherapy for lung metastases in three patients with pediatric malignancies.

Authors:  Jared Deck; Gary Eastwick; Jody Sima; Amanda Raymond; Jeffrey Bogart; Paul Aridgides
Journal:  Onco Targets Ther       Date:  2019-05-15       Impact factor: 4.147

Review 5.  Current and Future Treatment Strategies for Rhabdomyosarcoma.

Authors:  Celine Chen; Heathcliff Dorado Garcia; Monika Scheer; Anton G Henssen
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

6.  Cardiac-Sparing and Breast-Sparing Whole Lung Irradiation Using Intensity-Modulated Proton Therapy.

Authors:  Ru Xin Wong; Jacqueline Faught; Melissa Gargone; William Myers; Matthew Krasin; Austin Faught; Sahaja Acharya
Journal:  Int J Part Ther       Date:  2021-03-09

7.  Prognostic Value of Circulating IGFBP2 and Related Autoantibodies in Children with Metastatic Rhabdomyosarcomas.

Authors:  Elena Poli; Angelica Zin; Manuela Cattelan; Lucia Tombolan; Ilaria Zanetti; Angela Scagnellato; Paolo Bonvini; Gianni Bisogno
Journal:  Diagnostics (Basel)       Date:  2020-02-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.